Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients
Purpose The aim of this study was to compare the difference in disease-free survival (DFS) and overall survival (OS) between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) in our Hispanic population with breast cancer (BC). Methods We retrospectively analyzed a database of 4533...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2019-07, Vol.176 (1), p.243-249 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 249 |
|---|---|
| container_issue | 1 |
| container_start_page | 243 |
| container_title | Breast cancer research and treatment |
| container_volume | 176 |
| creator | Flores-Díaz, Diana Arce, Claudia Flores-Luna, Lourdes Reynoso-Noveron, Nancy Lara-Medina, Fernando Matus, Juan Antonio Bargallo-Rocha, Enrique Pérez, Víctor Villarreal-Garza, Cynthia Cabrera-Galeana, Paula Mohar, Alejandro |
| description | Purpose
The aim of this study was to compare the difference in disease-free survival (DFS) and overall survival (OS) between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) in our Hispanic population with breast cancer (BC).
Methods
We retrospectively analyzed a database of 4533 non-metastatic BC patients treated for BC at the National Cancer Institute in Mexico (INCan) between 2006 and 2016. We compared clinical characteristics, treatment and survival between women with invasive ductal and invasive lobular BC. We evaluated differences between survival curves with the log-rank test and used Cox’s proportional hazards model for the multivariate analysis.
Results
Median follow-up time was 42.13 months (IQ
25
25.2–IQ
75
72.06). The median age was 50.9 years (IQ
25
43.5–IQ
75
59.8). DFS at 5 years was 80.8% for IDC versus 76.2% for ILC. 5 years OS was 88.7% for IDC versus 84.3% for ILC. Multivariate analysis showed that factors that negatively affected the 5-year DFS include: clinical stage III [hazard ratio (HR) 4.2, 95% CI 3.36–5.35;
p
|
| doi_str_mv | 10.1007/s10549-019-05234-8 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2211326785</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A587803028</galeid><sourcerecordid>A587803028</sourcerecordid><originalsourceid>FETCH-LOGICAL-c473t-b5526c3753bc537c499d41ec74e564be28f3e22f0e3cff510e94a74076b73b373</originalsourceid><addsrcrecordid>eNp9kV1rFTEQhoNY7LH6B7yQBUG82TpJNju7l6X4UWjpTb0TQjZn9jRlNzkm2VL_vTmeaq2IhBCYPM8ww8vYKw7HHADfJw6q6Wvg5Sohm7p7wlZcoaxRcHzKVsBbrNsO2kP2PKUbAOgR-mfsUELfYyvkin09m7fG5iqMlfO3JrlbqqYwLJOJlTXROh9mUwVfin5TZ4pzFZZsw0ypCNUF3TlrfDVEMikXw1uK1dZkRz6nF-xgNFOil_fvEfvy8cPV6ef6_PLT2enJeW0blLkelBKtlajkYJVE2_T9uuFksSHVNgOJbpQkxAgk7TgqDtQ3BhvAdkA5SJRH7N2-7zaGbwulrGeXLE2T8RSWpIXgXIoWO1XQN3-hN2GJvky3o6DjHFE8UBszkXZ-DDkau2uqT1SHHUgQXaGO_0GVs6bZ2eBpdKX-SHj7h3BNZsrXKUxLdsGnx6DYgzaGlCKNehvdbOJ3zUHvstf77HXJXv_MXu-k1_erLcNM69_Kr7ALIPdAKl9-Q_Fh9_-0_QFoXLaV</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2210811772</pqid></control><display><type>article</type><title>Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients</title><source>SpringerLink Journals</source><creator>Flores-Díaz, Diana ; Arce, Claudia ; Flores-Luna, Lourdes ; Reynoso-Noveron, Nancy ; Lara-Medina, Fernando ; Matus, Juan Antonio ; Bargallo-Rocha, Enrique ; Pérez, Víctor ; Villarreal-Garza, Cynthia ; Cabrera-Galeana, Paula ; Mohar, Alejandro</creator><creatorcontrib>Flores-Díaz, Diana ; Arce, Claudia ; Flores-Luna, Lourdes ; Reynoso-Noveron, Nancy ; Lara-Medina, Fernando ; Matus, Juan Antonio ; Bargallo-Rocha, Enrique ; Pérez, Víctor ; Villarreal-Garza, Cynthia ; Cabrera-Galeana, Paula ; Mohar, Alejandro</creatorcontrib><description>Purpose
The aim of this study was to compare the difference in disease-free survival (DFS) and overall survival (OS) between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) in our Hispanic population with breast cancer (BC).
Methods
We retrospectively analyzed a database of 4533 non-metastatic BC patients treated for BC at the National Cancer Institute in Mexico (INCan) between 2006 and 2016. We compared clinical characteristics, treatment and survival between women with invasive ductal and invasive lobular BC. We evaluated differences between survival curves with the log-rank test and used Cox’s proportional hazards model for the multivariate analysis.
Results
Median follow-up time was 42.13 months (IQ
25
25.2–IQ
75
72.06). The median age was 50.9 years (IQ
25
43.5–IQ
75
59.8). DFS at 5 years was 80.8% for IDC versus 76.2% for ILC. 5 years OS was 88.7% for IDC versus 84.3% for ILC. Multivariate analysis showed that factors that negatively affected the 5-year DFS include: clinical stage III [hazard ratio (HR) 4.2, 95% CI 3.36–5.35;
p
< 0.001], triple negative phenotype (HR 1.4, 95% CI 1.08–1.81;
p
= 0.009), Ki67 ≥ 18 (HR 1.6, 95% CI 1.28–2.11;
p
< 0.001), and lobular histological type (HR 1.6, 95% CI 1.09–2.49;
p
= 0.017). Factors associated with a negative impact on OS were: clinical stage III (HR 4.5, 95% CI 3.15–6.54;
p
< 0.001), triple negative phenotype (HR 2.4, 95% CI 1.69–3.48;
p
< 0.001), and Ki67 ≥ 18% (HR 1.9, 95% CI 1.27–2.92;
p
= 0.02).
Conclusion
Our results highlight the different biology of ILC and show that long-term prognosis in terms of DFS is not as favorable as previously reported.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-019-05234-8</identifier><identifier>PMID: 30997623</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Breast cancer ; Cancer patients ; Cancer research ; Care and treatment ; Comparative analysis ; Epidemiology ; Invasiveness ; Medical prognosis ; Medicine ; Medicine & Public Health ; Metastases ; Metastasis ; Multivariate analysis ; Oncology ; Patient outcomes ; Patients ; Phenotypes ; Survival</subject><ispartof>Breast cancer research and treatment, 2019-07, Vol.176 (1), p.243-249</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2019</rights><rights>COPYRIGHT 2019 Springer</rights><rights>Breast Cancer Research and Treatment is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c473t-b5526c3753bc537c499d41ec74e564be28f3e22f0e3cff510e94a74076b73b373</citedby><cites>FETCH-LOGICAL-c473t-b5526c3753bc537c499d41ec74e564be28f3e22f0e3cff510e94a74076b73b373</cites><orcidid>0000-0002-4730-4787</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-019-05234-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-019-05234-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30997623$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Flores-Díaz, Diana</creatorcontrib><creatorcontrib>Arce, Claudia</creatorcontrib><creatorcontrib>Flores-Luna, Lourdes</creatorcontrib><creatorcontrib>Reynoso-Noveron, Nancy</creatorcontrib><creatorcontrib>Lara-Medina, Fernando</creatorcontrib><creatorcontrib>Matus, Juan Antonio</creatorcontrib><creatorcontrib>Bargallo-Rocha, Enrique</creatorcontrib><creatorcontrib>Pérez, Víctor</creatorcontrib><creatorcontrib>Villarreal-Garza, Cynthia</creatorcontrib><creatorcontrib>Cabrera-Galeana, Paula</creatorcontrib><creatorcontrib>Mohar, Alejandro</creatorcontrib><title>Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Purpose
The aim of this study was to compare the difference in disease-free survival (DFS) and overall survival (OS) between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) in our Hispanic population with breast cancer (BC).
Methods
We retrospectively analyzed a database of 4533 non-metastatic BC patients treated for BC at the National Cancer Institute in Mexico (INCan) between 2006 and 2016. We compared clinical characteristics, treatment and survival between women with invasive ductal and invasive lobular BC. We evaluated differences between survival curves with the log-rank test and used Cox’s proportional hazards model for the multivariate analysis.
Results
Median follow-up time was 42.13 months (IQ
25
25.2–IQ
75
72.06). The median age was 50.9 years (IQ
25
43.5–IQ
75
59.8). DFS at 5 years was 80.8% for IDC versus 76.2% for ILC. 5 years OS was 88.7% for IDC versus 84.3% for ILC. Multivariate analysis showed that factors that negatively affected the 5-year DFS include: clinical stage III [hazard ratio (HR) 4.2, 95% CI 3.36–5.35;
p
< 0.001], triple negative phenotype (HR 1.4, 95% CI 1.08–1.81;
p
= 0.009), Ki67 ≥ 18 (HR 1.6, 95% CI 1.28–2.11;
p
< 0.001), and lobular histological type (HR 1.6, 95% CI 1.09–2.49;
p
= 0.017). Factors associated with a negative impact on OS were: clinical stage III (HR 4.5, 95% CI 3.15–6.54;
p
< 0.001), triple negative phenotype (HR 2.4, 95% CI 1.69–3.48;
p
< 0.001), and Ki67 ≥ 18% (HR 1.9, 95% CI 1.27–2.92;
p
= 0.02).
Conclusion
Our results highlight the different biology of ILC and show that long-term prognosis in terms of DFS is not as favorable as previously reported.</description><subject>Breast cancer</subject><subject>Cancer patients</subject><subject>Cancer research</subject><subject>Care and treatment</subject><subject>Comparative analysis</subject><subject>Epidemiology</subject><subject>Invasiveness</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Multivariate analysis</subject><subject>Oncology</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Phenotypes</subject><subject>Survival</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kV1rFTEQhoNY7LH6B7yQBUG82TpJNju7l6X4UWjpTb0TQjZn9jRlNzkm2VL_vTmeaq2IhBCYPM8ww8vYKw7HHADfJw6q6Wvg5Sohm7p7wlZcoaxRcHzKVsBbrNsO2kP2PKUbAOgR-mfsUELfYyvkin09m7fG5iqMlfO3JrlbqqYwLJOJlTXROh9mUwVfin5TZ4pzFZZsw0ypCNUF3TlrfDVEMikXw1uK1dZkRz6nF-xgNFOil_fvEfvy8cPV6ef6_PLT2enJeW0blLkelBKtlajkYJVE2_T9uuFksSHVNgOJbpQkxAgk7TgqDtQ3BhvAdkA5SJRH7N2-7zaGbwulrGeXLE2T8RSWpIXgXIoWO1XQN3-hN2GJvky3o6DjHFE8UBszkXZ-DDkau2uqT1SHHUgQXaGO_0GVs6bZ2eBpdKX-SHj7h3BNZsrXKUxLdsGnx6DYgzaGlCKNehvdbOJ3zUHvstf77HXJXv_MXu-k1_erLcNM69_Kr7ALIPdAKl9-Q_Fh9_-0_QFoXLaV</recordid><startdate>20190701</startdate><enddate>20190701</enddate><creator>Flores-Díaz, Diana</creator><creator>Arce, Claudia</creator><creator>Flores-Luna, Lourdes</creator><creator>Reynoso-Noveron, Nancy</creator><creator>Lara-Medina, Fernando</creator><creator>Matus, Juan Antonio</creator><creator>Bargallo-Rocha, Enrique</creator><creator>Pérez, Víctor</creator><creator>Villarreal-Garza, Cynthia</creator><creator>Cabrera-Galeana, Paula</creator><creator>Mohar, Alejandro</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4730-4787</orcidid></search><sort><creationdate>20190701</creationdate><title>Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients</title><author>Flores-Díaz, Diana ; Arce, Claudia ; Flores-Luna, Lourdes ; Reynoso-Noveron, Nancy ; Lara-Medina, Fernando ; Matus, Juan Antonio ; Bargallo-Rocha, Enrique ; Pérez, Víctor ; Villarreal-Garza, Cynthia ; Cabrera-Galeana, Paula ; Mohar, Alejandro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c473t-b5526c3753bc537c499d41ec74e564be28f3e22f0e3cff510e94a74076b73b373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Breast cancer</topic><topic>Cancer patients</topic><topic>Cancer research</topic><topic>Care and treatment</topic><topic>Comparative analysis</topic><topic>Epidemiology</topic><topic>Invasiveness</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Multivariate analysis</topic><topic>Oncology</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Phenotypes</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Flores-Díaz, Diana</creatorcontrib><creatorcontrib>Arce, Claudia</creatorcontrib><creatorcontrib>Flores-Luna, Lourdes</creatorcontrib><creatorcontrib>Reynoso-Noveron, Nancy</creatorcontrib><creatorcontrib>Lara-Medina, Fernando</creatorcontrib><creatorcontrib>Matus, Juan Antonio</creatorcontrib><creatorcontrib>Bargallo-Rocha, Enrique</creatorcontrib><creatorcontrib>Pérez, Víctor</creatorcontrib><creatorcontrib>Villarreal-Garza, Cynthia</creatorcontrib><creatorcontrib>Cabrera-Galeana, Paula</creatorcontrib><creatorcontrib>Mohar, Alejandro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Flores-Díaz, Diana</au><au>Arce, Claudia</au><au>Flores-Luna, Lourdes</au><au>Reynoso-Noveron, Nancy</au><au>Lara-Medina, Fernando</au><au>Matus, Juan Antonio</au><au>Bargallo-Rocha, Enrique</au><au>Pérez, Víctor</au><au>Villarreal-Garza, Cynthia</au><au>Cabrera-Galeana, Paula</au><au>Mohar, Alejandro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2019-07-01</date><risdate>2019</risdate><volume>176</volume><issue>1</issue><spage>243</spage><epage>249</epage><pages>243-249</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><abstract>Purpose
The aim of this study was to compare the difference in disease-free survival (DFS) and overall survival (OS) between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) in our Hispanic population with breast cancer (BC).
Methods
We retrospectively analyzed a database of 4533 non-metastatic BC patients treated for BC at the National Cancer Institute in Mexico (INCan) between 2006 and 2016. We compared clinical characteristics, treatment and survival between women with invasive ductal and invasive lobular BC. We evaluated differences between survival curves with the log-rank test and used Cox’s proportional hazards model for the multivariate analysis.
Results
Median follow-up time was 42.13 months (IQ
25
25.2–IQ
75
72.06). The median age was 50.9 years (IQ
25
43.5–IQ
75
59.8). DFS at 5 years was 80.8% for IDC versus 76.2% for ILC. 5 years OS was 88.7% for IDC versus 84.3% for ILC. Multivariate analysis showed that factors that negatively affected the 5-year DFS include: clinical stage III [hazard ratio (HR) 4.2, 95% CI 3.36–5.35;
p
< 0.001], triple negative phenotype (HR 1.4, 95% CI 1.08–1.81;
p
= 0.009), Ki67 ≥ 18 (HR 1.6, 95% CI 1.28–2.11;
p
< 0.001), and lobular histological type (HR 1.6, 95% CI 1.09–2.49;
p
= 0.017). Factors associated with a negative impact on OS were: clinical stage III (HR 4.5, 95% CI 3.15–6.54;
p
< 0.001), triple negative phenotype (HR 2.4, 95% CI 1.69–3.48;
p
< 0.001), and Ki67 ≥ 18% (HR 1.9, 95% CI 1.27–2.92;
p
= 0.02).
Conclusion
Our results highlight the different biology of ILC and show that long-term prognosis in terms of DFS is not as favorable as previously reported.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>30997623</pmid><doi>10.1007/s10549-019-05234-8</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-4730-4787</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2019-07, Vol.176 (1), p.243-249 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2211326785 |
| source | SpringerLink Journals |
| subjects | Breast cancer Cancer patients Cancer research Care and treatment Comparative analysis Epidemiology Invasiveness Medical prognosis Medicine Medicine & Public Health Metastases Metastasis Multivariate analysis Oncology Patient outcomes Patients Phenotypes Survival |
| title | Impact of invasive lobular carcinoma on long-term outcomes in Mexican breast cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T04%3A30%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20invasive%20lobular%20carcinoma%20on%20long-term%20outcomes%20in%20Mexican%20breast%20cancer%20patients&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Flores-D%C3%ADaz,%20Diana&rft.date=2019-07-01&rft.volume=176&rft.issue=1&rft.spage=243&rft.epage=249&rft.pages=243-249&rft.issn=0167-6806&rft.eissn=1573-7217&rft_id=info:doi/10.1007/s10549-019-05234-8&rft_dat=%3Cgale_proqu%3EA587803028%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2210811772&rft_id=info:pmid/30997623&rft_galeid=A587803028&rfr_iscdi=true |